Article Text

other Versions

PDF
Letter
Author's response to: HBV seromarkers clearance and risk of hepatocellular carcinoma: serious risks of misinterpretation
  1. Jessica Liu1,
  2. Hwai-I Yang1,2,3,
  3. Chien-Jen Chen1,4
  1. 1The Genomics Research Center, Academia Sinica, Taipei, Taiwan
  2. 2Molecular and Genomic Epidemiology Center, China Medical University Hospital, Taichung, Taiwan
  3. 3Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan
  4. 4Graduate Institute of Epidemiology and Preventative Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
  1. Correspondence to Professor Chien-Jen Chen, The Genomics Research Center, Academia Sinica, 128 Academia Road, Section 2, Nangang, Taipei 115, Taiwan; chencj{at}gate.sinica.edu.tw.

Statistics from Altmetric.com

We would like to respond to Dr Pariente's letter, which addresses our recently reported results regarding the seroclearance of HBV seromarkers and subsequent risk for hepatocellular carcinoma (HCC).1 ,2 Unfortunately, his comments are based on serious misunderstandings of our findings.

First, he suggests that there may be underestimation of the protective roles of marker seroclearance, since incidence rates of HCC were measured from baseline, and that the duration of seromarkers’ positivity would be a better indicator of HCC risk. In order to truly measure the effect of HBV DNA and Hepatitis B surface Antigen (HBsAg) seroclearance on HCC incidence, we would need a large cohort of individuals followed up since birth for subsequent outcomes. However, this was not feasible in this study. Thus, left truncation that …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles